Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

HIV and women

Lisa Hirschhorn, MD, MPH
Section Editor
John G Bartlett, MD
Deputy Editor
Allyson Bloom, MD


Women represent one of the fastest growing populations infected with the human immunodeficiency virus (HIV) in the United States. While many of the clinical manifestations of HIV/AIDS in women are similar to men, there remain significant gender-based differences in the disease. These include:

Differences in viral load early in infection

Differences in selected opportunistic infections

Difference in selected ARV-related toxicities and side effects

A number of female-specific complications


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Mar 31, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Centers for Disease Control and Prevention. HIV surveillance report, 2011; vol. 23. http://www.cdc.gov/hiv/library/reports/surveillance/index.html (Accessed on February 01, 2013).
  2. Centers for Disease Control and Prevention (CDC). Diagnoses of HIV/AIDS--32 States, 2000-2003. MMWR Morb Mortal Wkly Rep 2004; 53:1106.
  3. Hader SL, Smith DK, Moore JS, Holmberg SD. HIV infection in women in the United States: status at the Millennium. JAMA 2001; 285:1186.
  4. Chu SY, Diaz T. Living situation of women with AIDS. J Acquir Immune Defic Syndr 1993; 6:431.
  5. Zierler S, Krieger N. Reframing women's risk: social inequalities and HIV infection. Annu Rev Public Health 1997; 18:401.
  6. Chersich MF, Rees HV. Vulnerability of women in southern Africa to infection with HIV: biological determinants and priority health sector interventions. AIDS 2008; 22 Suppl 4:S27.
  7. Wira CR, Fahey JV. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008; 22:1909.
  8. Polis CB, Phillips SJ, Curtis KM, et al. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception 2014; 90:360.
  9. Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med 2015; 12:e1001778.
  10. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis 2015; 15:181.
  11. Achilles SL, Creinin MD, Stoner KA, et al. Changes in genital tract immune cell populations after initiation of intrauterine contraception. Am J Obstet Gynecol 2014; 211:489.e1.
  12. Ellerbrock TV, Bush TJ, Chamberland ME, Oxtoby MJ. Epidemiology of women with AIDS in the United States, 1981 through 1990. A comparison with heterosexual men with AIDS. JAMA 1991; 265:2971.
  13. Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1994; 272:1915.
  14. Hirschhorn LR. HIV infection in women: Is it different. AIDS Reader 1995; 5:99.
  15. Cozzi Lepri A, Pezzotti P, Dorrucci M, et al. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study. BMJ 1994; 309:1537.
  16. Laine C, Markson LE, McKee LJ, et al. The relationship of clinic experience with advanced HIV and survival of women with AIDS. AIDS 1998; 12:417.
  17. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005; 38:96.
  18. Centers for Disease Control and Prevention (CDC). Update: trends in AIDS incidence -- United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:861.
  19. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr 2000; 25:115.
  20. Hirschhorn LR, McInnes K, Landon BE, et al. Gender differences in quality of HIV care in Ryan White CARE Act-funded clinics. Womens Health Issues 2006; 16:104.
  21. Cornell M, Schomaker M, Garone DB, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med 2012; 9:e1001304.
  22. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285:1466.
  23. Rumptz MH, Tobias C, Rajabiun S, et al. Factors associated with engaging socially marginalized HIV-positive persons in primary care. AIDS Patient Care STDS 2007; 21 Suppl 1:S30.
  24. Gruskin L, Gange SJ, Celentano D, et al. Incidence of violence against HIV-infected and uninfected women: findings from the HIV Epidemiology Research (HER) study. J Urban Health 2002; 79:512.
  25. The White House Office of National AIDS Policy. (2010). National HIV/AIDS strategy for theUnited States. http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf (Accessed on October 17, 2013).
  26. Messer LC, Quinlivan EB, Parnell H, et al. Barriers and facilitators to testing, treatment entry, and engagement in care by HIV-positive women of color. AIDS Patient Care STDS 2013; 27:398.
  27. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012; 156:817.
  28. http://www.incarecampaign.org/ (Accessed on October 17, 2013).
  29. Horberg MA, Hurley LB, Klein DB, et al. The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS 2015; 29:582.
  30. Clark RA, Brandon W, Dumestre J, Pindaro C. Clinical manifestations of infection with the human immunodeficiency virus in women in Louisiana. Clin Infect Dis 1993; 17:165.
  31. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352:1510.
  32. Gandhi M, Bacchetti P, Miotti P, et al. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 2002; 35:313.
  33. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720.
  34. Long EM, Martin HL Jr, Kreiss JK, et al. Gender differences in HIV-1 diversity at time of infection. Nat Med 2000; 6:71.
  35. Fleming PL, Ciesielski CA, Byers RH, et al. Gender differences in reported AIDS-indicative diagnoses. J Infect Dis 1993; 168:61.
  36. Cooley TP, Hirschhorn LR, O'Keane JC. Kaposi's sarcoma in women with AIDS. AIDS 1996; 10:1221.
  37. Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 2003; 101:548.
  38. Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:219.
  39. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997; 126:689.
  40. Jamieson DJ, Duerr A, Klein RS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol 2001; 98:656.
  41. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
  42. Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis 2005; 192:1372.
  43. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76:369.
  44. LaGuardia KD, White MH, Saigo PE, et al. Genital ulcer disease in women infected with human immunodeficiency virus. Am J Obstet Gynecol 1995; 172:553.
  45. Risbud A, Chan-Tack K, Gadkari D, et al. The etiology of genital ulcer disease by multiplex polymerase chain reaction and relationship to HIV infection among patients attending sexually transmitted disease clinics in Pune, India. Sex Transm Dis 1999; 26:55.
  46. Korn AP, Landers DV, Green JR, Sweet RL. Pelvic inflammatory disease in human immunodeficiency virus-infected women. Obstet Gynecol 1993; 82:765.
  47. Barbosa C, Macasaet M, Brockmann S, et al. Pelvic inflammatory disease and human immunodeficiency virus infection. Obstet Gynecol 1997; 89:65.
  48. Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000; 95:525.
  49. Cohen CR, Sinei S, Reilly M, et al. Effect of human immunodeficiency virus type 1 infection upon acute salpingitis: a laparoscopic study. J Infect Dis 1998; 178:1352.
  50. Duerr A, Kieke B, Warren D, et al. Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184:584.
  51. Jamieson DJ, Duerr A, Burk R, et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol 2002; 186:21.
  52. Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591.
  53. Mandelblatt JS, Kanetsky P, Eggert L, Gold K. Is HIV infection a cofactor for cervical squamous cell neoplasia? Cancer Epidemiol Biomarkers Prev 1999; 8:97.
  54. Harris TG, Burk RD, Xue X, et al. Association of cutaneous anergy with human papillomavirus and cervical neoplasia in HIV-seropositive and seronegative women. AIDS 2007; 21:1933.
  55. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031.
  56. Vernon SD, Holmes KK, Reeves WC. Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1:S121.
  57. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226.
  58. Ahdieh L, Muñoz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000; 151:1148.
  59. Rowhani-Rahbar A, Hawes SE, Sow PS, et al. The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis 2007; 196:887.
  60. Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005; 293:1471.
  61. Keller MJ, Burk RD, Xie X, et al. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. JAMA 2012; 308:362.
  62. Maiman M, Fruchter RG, Guy L, et al. Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer 1993; 71:402.
  63. Massad LS, Evans C, Weber K, et al. Hysterectomy among women with HIV: indications and incidence. J Acquir Immune Defic Syndr 2007; 44:566.
  64. Luque AE, Jabeen M, Messing S, et al. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis 2006; 194:428.
  65. Taylor G, Wolff T, Khanna N, et al. Genital dysplasia in women infected with human immunodeficiency virus. J Am Board Fam Pract 2004; 17:108.
  66. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425.
  67. Xi LF, Kiviat NB. Cervical neoplasia and highly active antiretroviral therapy. J Natl Cancer Inst 2004; 96:1051.
  68. Shiels MS, Pfeiffer RM, Hall HI, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 2011; 305:1450.
  69. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010; 201:681.
  70. Anderson JR, Paramsothy P, Heilig C, et al. Accuracy of Papanicolaou test among HIV-infected women. Clin Infect Dis 2006; 42:562.
  71. Wright TC Jr, Moscarelli RD, Dole P, et al. Significance of mild cytologic atypia in women infected with human immunodeficiency virus. Obstet Gynecol 1996; 87:515.
  72. Duerr A, Paramsothy P, Jamieson DJ, et al. Effect of HIV infection on atypical squamous cells of undetermined significance. Clin Infect Dis 2006; 42:855.
  73. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on October 20, 2015).
  74. Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58:e1.
  75. Moyer VA, U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156:880.
  76. Keller MJ, Burk RD, Massad LS, et al. Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test. Clin Infect Dis 2015; 61:1573.
  77. Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.
  78. Massad LS, Silverberg MJ, Springer G, et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol 2004; 190:1241.
  79. Hou JY, Smotkin D, Grossberg R, et al. High prevalence of high grade anal intraepithelial neoplasia in HIV-infected women screened for anal cancer. J Acquir Immune Defic Syndr 2012; 60:169.
  80. Schoenbaum EE, Hartel D, Lo Y, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 2005; 41:1517.
  81. Ellerbrock TV, Wright TC, Bush TJ, et al. Characteristics of menstruation in women infected with human immunodeficiency virus. Obstet Gynecol 1996; 87:1030.
  82. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.
  83. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415.
  84. Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006; 42:584.
  85. Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:38.
  86. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489.
  87. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on May 01, 2014).
  88. Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:410.
  89. Prins M, Meyer L, Hessol NA. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS 2005; 19:357.
  90. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32:452.
  91. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24:475.
  92. Struble K, Soon G, Min M, et al. Meta-analysis of Efficacy Outcomes for Treatment-naïve and Treatment-experienced HIV-infected Women in Randomized Controlled Clinical Trials: 2000 to 2008. 17th Conference on Retroviruses and Opportunistic Infections. February 16-19, 20010; San Francisco, California. Abstract 987b.
  93. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 2010; 153:349.
  94. Smith KY, Tierney C, Mollan K, et al. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis 2014; 58:555.
  95. Collazos J, Asensi V, Cartón JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007; 21:835.
  96. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81.
  97. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124.
  98. Mazhude C, Jones S, Murad S, et al. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002; 16:1566.
  99. Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13:465.
  100. Maki PM, Rubin LH, Valcour V, et al. Cognitive function in women with HIV: findings from the Women's Interagency HIV Study. Neurology 2015; 84:231.
  101. Williams A, Friedland G. Adherence, compliance, and HAART. AIDS Clin Care 1997; 9:51.
  102. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010; 153:452.
  103. Martin CP, Fain MJ, Klotz SA. The older HIV-positive adult: a critical review of the medical literature. Am J Med 2008; 121:1032.
  104. Katz MH, Cunningham WE, Fleishman JA, et al. Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons. Ann Intern Med 2001; 135:557.
  105. http://www.aidsetc.org/aetc?page=cm-307_women (Accessed on November 13, 2010).
  106. Pyra M, Heffron R, Mugo NR, et al. Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. AIDS 2015; 29:2353.
  107. Scarsi KK, Darin KM, Nakalema S, et al. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. Clin Infect Dis 2016; 62:675.
  108. Perry SH, Swamy P, Preidis GA, et al. Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. AIDS 2014; 28:791.
  109. Patel RC, Onono M, Gandhi M, et al. Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. Lancet HIV 2015; 2:e474.
  110. Database of Antiretroviral Drug Interactions. HIV InSite. http://arv.ucsf.edu/insite?page=ar-00-02.
  111. HIV Drug Interaction Checker. University of Liverpool. http://www.hiv-druginteractions.org/.
  112. Stringer EM, Levy J, Sinkala M, et al. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS 2009; 23:1377.
  113. Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007; 197:144.e1.
  114. Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006; 42:1333.
  115. Richardson BA, Otieno PA, Mbori-Ngacha D, et al. Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS 2007; 21:749.
  116. Cejtin HE, Jacobson L, Springer G, et al. Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women. AIDS 2003; 17:1702.
  117. Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 2006; 21:2857.
  118. Heikinheimo O, Lehtovirta P, Aho I, et al. The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. Am J Obstet Gynecol 2011; 204:126.e1.
  119. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994; 331:341.
  120. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; :CD003255.
  121. Fontanet AL, Saba J, Chandelying V, et al. Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS 1998; 12:1851.
  122. Cates W Jr, Stone KM. Family planning, sexually transmitted diseases and contraceptive choice: a literature update--Part I. Fam Plann Perspect 1992; 24:75.
  123. Kelaghan J, Rubin GL, Ory HW, Layde PM. Barrier-method contraceptives and pelvic inflammatory disease. JAMA 1982; 248:184.
  124. Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol 2003; 101:797.
  125. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0/ (Accessed on March 28, 2014).